Belgium· BE-AMP-SAM574986-00
Adakveo 10 mg/ml
A crizanlizumab product containing crizanlizumab, registered in Belgium by Novartis Europharm. The same ATC class is registered in 7 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Crizanlizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC B06AX01 (crizanlizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Crizanlizumab · ATC B06AX01
7 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Crizanlizumab
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- B06AX01
- ATC class
- Crizanlizumab
- Defined daily dose
- 12.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Crizanlizumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAdakveoNovartis Europharm Limited
- United StatesADAKVEONovartis Pharmaceuticals Corporation
- SpainADAKVEO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONNovartis Europharm Limited
- FranceADAKVEO 10 mg/mL, solution à diluer pour perfusionNOVARTIS EUROPHARM (IRLANDE)
- United KingdomAdakveo 100mg/10ml concentrate for solution for infusion vialsNovartis Pharmaceuticals UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a70d0b4-9c3d-4661-aa5c-a30ea05d367c GET /v1/drugs/0a70d0b4-9c3d-4661-aa5c-a30ea05d367c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "REVOKED",
"name_en": "Adakveo 10 mg/ml",
"name_fr": "Adakveo 10 mg/ml",
"name_nl": "Adakveo 10 mg/ml",
"amp_code": "SAM574986-00",
"strengths": [
"10.0000",
"10.0000"
],
"pack_count": 1,
"substances": [
"Crizanlizumab",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Crizanlizumab",
"authorisation_numbers": [
"EU/1/20/1476/001"
]
}See everything about crizanlizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.